Yamo Launches Global Registry to Accelerate Autism Drug Trials

The company’s decision follows a spike in interest after recent media coverage highlighted the potential of L1-79. Unlike existing FDA-approved medications that primarily target associated behaviors like irritability, L1-79 is designed to address core symptoms such as social communication impairments and repetitive behaviors. Data from Phase 2 trials showed statistically significant improvements in these areas with a favorable safety profile, positioning the drug as a potential breakthrough for individuals with profound autism.

CEO Chuck Bramlage noted that the registry serves as a direct line to families waiting for clinical site openings scheduled for early 2027. While registration does not guarantee enrollment—which remains subject to strict eligibility criteria and pre-screening at U.S. clinical sites—the portal ensures that caregivers remain updated as the study progresses. With autism affecting approximately one in 31 children in the United States, the pressure to bring L1-79 to market is high. Yamo is currently coordinating with federal authorities to navigate the path toward the pivotal Phase 3 program, aiming to deliver the first treatment specifically engineered to target the underlying neurological features of the disorder.